New Risk • 17h
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$261m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company. Reported Earnings • 17h
Second quarter 2026 earnings released: NT$0.02 loss per share (vs NT$0.33 loss in 2Q 2025) Second quarter 2026 results: NT$0.02 loss per share (improved from NT$0.33 loss in 2Q 2025). Revenue: NT$188.1m (up 67% from 2Q 2025). Net loss: NT$1.65m (loss narrowed 90% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. New Risk • Jul 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.21b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$3.21b market cap, or US$99.0m). Board Change • Jul 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Jul 07
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Shun-xiong Xu was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 17
Full year 2025 earnings released: NT$0.92 loss per share (vs NT$1.49 loss in FY 2024) Full year 2025 results: NT$0.92 loss per share. Revenue: NT$346.1m (down 26% from FY 2024). Net loss: NT$49.6m (loss widened 2.1% from FY 2024). Ankündigung • Feb 09
Sagittarius Life Science Corp, Annual General Meeting, May 06, 2026 Sagittarius Life Science Corp, Annual General Meeting, May 06, 2026, at 09:30 Taipei Standard Time. Location: no,2, kung yeh rd., guantian district, tainan city Taiwan Reported Earnings • Nov 19
Third quarter 2025 earnings released: NT$0.10 loss per share (vs NT$0.45 loss in 3Q 2024) Third quarter 2025 results: NT$0.10 loss per share (improved from NT$0.45 loss in 3Q 2024). Revenue: NT$92.9m (down 19% from 3Q 2024). Net loss: NT$6.77m (loss narrowed 54% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. New Risk • Nov 17
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.09b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$3.09b market cap, or US$99.2m). New Risk • Sep 14
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 108% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Shareholders have been substantially diluted in the past year (108% increase in shares outstanding). Reported Earnings • Aug 17
Second quarter 2025 earnings released: NT$0.33 loss per share (vs NT$0.50 loss in 2Q 2024) Second quarter 2025 results: NT$0.33 loss per share (improved from NT$0.50 loss in 2Q 2024). Revenue: NT$112.7m (down 4.8% from 2Q 2024). Net loss: NT$15.7m (loss narrowed 3.9% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. New Risk • May 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (NT$1.07b market cap, or US$35.5m). Reported Earnings • May 18
First quarter 2025 earnings released: NT$0.48 loss per share (vs NT$0.29 loss in 1Q 2024) First quarter 2025 results: NT$0.48 loss per share (further deteriorated from NT$0.29 loss in 1Q 2024). Revenue: NT$100.9m (down 14% from 1Q 2024). Net loss: NT$15.7m (loss widened 68% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Ankündigung • Feb 06
Sagittarius Life Science Corp, Annual General Meeting, Apr 30, 2025 Sagittarius Life Science Corp, Annual General Meeting, Apr 30, 2025. Location: 3 floor building. f no,3, yuan ou st., nangang district, taipei city Taiwan Reported Earnings • Nov 19
Third quarter 2024 earnings released: NT$0.45 loss per share (vs NT$0.34 loss in 3Q 2023) Third quarter 2024 results: NT$0.45 loss per share (further deteriorated from NT$0.34 loss in 3Q 2023). Revenue: NT$114.5m (up 8.2% from 3Q 2023). Net loss: NT$14.7m (loss widened 34% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 17
Second quarter 2024 earnings released: NT$0.50 loss per share (vs NT$0.35 loss in 2Q 2023) Second quarter 2024 results: NT$0.50 loss per share (further deteriorated from NT$0.35 loss in 2Q 2023). Revenue: NT$118.3m (up 3.3% from 2Q 2023). Net loss: NT$16.4m (loss widened 43% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 19
First quarter 2024 earnings released: NT$0.29 loss per share (vs NT$0.43 loss in 1Q 2023) First quarter 2024 results: NT$0.29 loss per share (improved from NT$0.43 loss in 1Q 2023). Revenue: NT$117.0m (up 2.2% from 1Q 2023). Net loss: NT$9.35m (loss narrowed 33% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 13% per year. Ankündigung • Mar 30
Sagittarius Life Science Corp, Annual General Meeting, Jun 26, 2024 Sagittarius Life Science Corp, Annual General Meeting, Jun 26, 2024. Reported Earnings • Mar 25
Full year 2023 earnings released: NT$1.69 loss per share (vs NT$2.28 loss in FY 2022) Full year 2023 results: NT$1.69 loss per share (improved from NT$2.28 loss in FY 2022). Revenue: NT$440.5m (down 17% from FY 2022). Net loss: NT$55.0m (loss narrowed 26% from FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year. Reported Earnings • Aug 15
Second quarter 2023 earnings released: NT$0.35 loss per share (vs NT$0.73 loss in 2Q 2022) Second quarter 2023 results: NT$0.35 loss per share (improved from NT$0.73 loss in 2Q 2022). Revenue: NT$114.6m (down 15% from 2Q 2022). Net loss: NT$11.5m (loss narrowed 52% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. New Risk • Jul 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.2% average weekly change). Minor Risk Market cap is less than US$100m (NT$1.80b market cap, or US$58.1m). Reported Earnings • Nov 16
Third quarter 2022 earnings released: NT$0.32 loss per share (vs NT$0.72 loss in 3Q 2021) Third quarter 2022 results: NT$0.32 loss per share (improved from NT$0.72 loss in 3Q 2021). Revenue: NT$136.0m (down 6.8% from 3Q 2021). Net loss: NT$10.5m (loss narrowed 55% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 13
Third quarter 2022 earnings released: NT$0.32 loss per share (vs NT$0.72 loss in 3Q 2021) Third quarter 2022 results: NT$0.32 loss per share (improved from NT$0.72 loss in 3Q 2021). Revenue: NT$136.0m (down 6.8% from 3Q 2021). Net loss: NT$10.5m (loss narrowed 55% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 19
Second quarter 2022 earnings released: NT$0.73 loss per share (vs NT$0.56 loss in 2Q 2021) Second quarter 2022 results: NT$0.73 loss per share (down from NT$0.56 loss in 2Q 2021). Revenue: NT$134.5m (down 13% from 2Q 2021). Net loss: NT$23.8m (loss widened 30% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 8% per year. Reported Earnings • May 19
First quarter 2022 earnings released: NT$0.65 loss per share (vs NT$0.68 loss in 1Q 2021) First quarter 2022 results: NT$0.65 loss per share (up from NT$0.68 loss in 1Q 2021). Revenue: NT$134.3m (down 8.9% from 1Q 2021). Net loss: NT$21.3m (loss narrowed 3.7% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 03
Full year 2021 earnings released: NT$2.66 loss per share (vs NT$2.27 loss in FY 2020) Full year 2021 results: NT$2.66 loss per share (down from NT$2.27 loss in FY 2020). Revenue: NT$587.6m (up 5.3% from FY 2020). Net loss: NT$86.4m (loss widened 17% from FY 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Ankündigung • Apr 02
Sagittarius Life Science Corp, Annual General Meeting, Jun 24, 2022 Sagittarius Life Science Corp, Annual General Meeting, Jun 24, 2022. Reported Earnings • Nov 15
Third quarter 2021 earnings released: NT$0.72 loss per share (vs NT$0.64 loss in 3Q 2020) The company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: NT$145.9m (up 13% from 3Q 2020). Net loss: NT$23.6m (loss widened 13% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 18
Second quarter 2021 earnings released: NT$0.56 loss per share (vs NT$0.72 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: NT$153.7m (up 14% from 2Q 2020). Net loss: NT$18.3m (loss narrowed 22% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Reported Earnings • May 18
First quarter 2021 earnings released: NT$0.68 loss per share (vs NT$0.31 loss in 1Q 2020) The company reported a poor first quarter result with increased losses and weaker control over costs, although revenues were flat. First quarter 2021 results: Revenue: NT$147.5m (flat on 1Q 2020). Net loss: NT$22.1m (loss widened 115% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 01
Full year 2020 earnings released: NT$2.27 loss per share (vs NT$3.65 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$558.2m (up 27% from FY 2019). Net loss: NT$74.1m (loss narrowed 38% from FY 2019). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Jan 21
New 90-day low: NT$31.50 The company is down 5.0% from its price of NT$33.25 on 23 October 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 10.0% over the same period. Is New 90 Day High Low • Jan 06
New 90-day low: NT$32.50 The company is down 7.0% from its price of NT$35.05 on 08 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 5.0% over the same period. Reported Earnings • Nov 15
Third quarter 2020 earnings released: NT$0.64 loss per share The company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$128.9m (up 13% from 3Q 2019). Net loss: NT$20.9m (loss narrowed 25% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Oct 16
New 90-day low: NT$33.95 The company is down 17% from its price of NT$41.15 on 17 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 9.0% over the same period. Is New 90 Day High Low • Sep 23
New 90-day low: NT$36.50 The company is down 14% from its price of NT$42.35 on 24 June 2020. The Taiwanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period. 
